OrbiMed Genesis Master Fund, L.P. Plans to Sell Common Stock of Disc Medicine, Inc.

OrbiMed Genesis Master Fund, L.P. has filed a Form 144 with the SEC, indicating its intention to sell 186,541 shares of common stock in Disc Medicine, Inc. The shares were acquired on December 29, 2022, through a business combination. The planned sale is expected to occur on or around October 20, 2025, with an aggregate market value of approximately $16,777,497.54. OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P., and OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC. The filing confirms that there have been no sales of securities in the past three months.